SETD2 and acute myeloid leukemia: Of interest, the presence of SETD2 mutations in 11q23/KMT2A‐rearranged AML showed a significant increased risk for relapse compared with SETD2 wildtype in 11q23/KMT2A‐rearranged AML (82% vs. 42%, PGray = 0.004).